Laura S. van Dam

731 citations

18 papers · 558 indexed · h-index 12

Immunology top 10%
Pulmonary and Respiratory Medicine top 10%
Oncology
Rheumatology top 10%
Molecular Biology

Co-authors: Ton J. Rabelink Y K Onno Teng Cees van Kooten Jaap Bakker Sylvia W.A. Kamerling Tineke Kraaij Hans Ulrich Scherer Obbo W Bredewold
Topics: Vasculitis and related conditions (10 papers)Neutrophil, Myeloperoxidase and Oxidative Mechanisms (6 papers)Cell Adhesion Molecules Research (5 papers)
Cited by: Immunology Rheumatology Genetics
Journals: PLoS ONE Kidney International Frontiers in Immunology
Partner nations: Netherlands United Kingdom United States

In The Last Decade

Laura S. van Dam

18 papers receiving 551 citations

Peers

Countries citing papers authored by Laura S. van Dam

Since Specialization

Citations

This map shows the geographic impact of Laura S. van Dam's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laura S. van Dam with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laura S. van Dam more than expected).

Fields of papers citing papers by Laura S. van Dam

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laura S. van Dam. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laura S. van Dam. The network helps show where Laura S. van Dam may publish in the future.

Co-authorship network of co-authors of Laura S. van Dam

This figure shows the co-authorship network connecting the top 25 collaborators of Laura S. van Dam. A scholar is included among the top collaborators of Laura S. van Dam based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laura S. van Dam. Laura S. van Dam is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work	Indexed citations
1	ExploriNg DUrable Remission with Rituximab in ANCA-associatEd vasculitis (ENDURRANCE trial): protocol for a randomised controlled trial 2022 ·BMJ Open ·(unknown),(unknown),Laura S. van Dam,Obbo W Bredewold,(unknown),Jacqueline T. Jonker,Darius Soonawala,(unknown),Bastiaan van Dam,Willem Jan W. Bos,(unknown),Joris I. Rotmans,Ton J. Rabelink,Y K Onno Teng	8
2	Compassionate Use of Avacopan in Difficult-to-Treat Antineutrophil Cytoplasmic Antibody–Associated Vasculitis 2021 ·Kidney International Reports ·(unknown),Obbo W Bredewold,Laura S. van Dam,(unknown),Jacqueline T. Jonker,(unknown),Antonius P. M. Langeveld,(unknown),(unknown),(unknown),Ton J. Rabelink,Y K Onno Teng	30
3	Highly Sensitive Flow Cytometric Detection of Residual B-Cells After Rituximab in Anti-Neutrophil Cytoplasmic Antibodies-Associated Vasculitis Patients 2020 ·Frontiers in Immunology ·Laura S. van Dam,(unknown),Sylvia W.A. Kamerling,(unknown),Obbo W Bredewold,Magdalena A. Berkowska,Jacques J. M. van Dongen,Ton J. Rabelink,Cees van Kooten,Y K Onno Teng	18
4	Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results 2020 ·Nephrology Dialysis Transplantation ·Tineke Kraaij,(unknown),Laura S. van Dam,Sylvia W.A. Kamerling,Paul Van Daele,Obbo W Bredewold,(unknown),Jaap Bakker,Hans Ulrich Scherer,T. Huizinga,Ton J. Rabelink,Cees van Kooten,Y K Onno Teng	60
5	P127 Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory SLE: two year results rituximab and belimumab combination for severe SLE 2020 ·Poster presentations ·Tineke Kraaij,(unknown),Laura S. van Dam,Sylvia W.A. Kamerling,Paul Van Daele,Obbo W Bredewold,(unknown),Jaap Bakker,Hans Ulrich Scherer,(unknown),Ton J. Rabelink,Cees van Kooten,(unknown)	2
6	PR3-ANCAs predict relapses in ANCA-associated vasculitis patients after rituximab 2020 ·Nephrology Dialysis Transplantation ·Laura S. van Dam,(unknown),Obbo W Bredewold,(unknown),Jaap Bakker,Cees van Kooten,Ton J. Rabelink,Y K Onno Teng	41
7	Obstetric and maternal outcomes in patients diagnosed with Hodgkin lymphoma during pregnancy: a multicentre, retrospective, cohort study 2019 ·The Lancet Haematology ·Charlotte Maggen,Daan Dierickx,Pieternella J. Lugtenburg,Annouschka Laenen,Elyce Cardonick,(unknown),Mar Bellido,(unknown),Mina Mhallem Gzirí,M Halaška,Petronella B. Ottevanger,Kristel Van Calsteren,(unknown),Evgeniya Polushkina,Laura S. van Dam,Irit Avivi,Peter Vandenberghe,Feng Jung Sherida H. Woei-A-Jin,Frédéric Amant	43
8	OP0042 LONG-TERM EFFECTS OF SYNERGETIC B CELL IMMUNOMODULATION WITH RITUXIMAB AND BELIMUMAB COMBINATION TREATMENT IN SEVERE, REFRACTORY SLE: TWO YEAR RESULTS 2019 ·Annals of the Rheumatic Diseases ·Tineke Kraaij,(unknown),Laura S. van Dam,Sylvia W.A. Kamerling,Paul Van Daele,Obbo W Bredewold,(unknown),Jaap Bakker,Ingeborg M. Bajema,Hans Ulrich Scherer,T. Huizinga,Ton J. Rabelink,Cees van Kooten,Y K Onno Teng	1
9	Intrinsically Distinct Role of Neutrophil Extracellular Trap Formation in Antineutrophil Cytoplasmic Antibody–Associated Vasculitis Compared to Systemic Lupus Erythematosus 2019 ·Arthritis & Rheumatology ·Laura S. van Dam,Tineke Kraaij,Sylvia W.A. Kamerling,Jaap Bakker,Hans Ulrich Scherer,Ton J. Rabelink,Cees van Kooten,Y K Onno Teng	64
10	A reverse translational study on the effect of rituximab, rituximab plus belimumab, or bortezomib on the humoral autoimmune response in SLE 2019 ·Lara D. Veeken ·Laura S. van Dam,(unknown),Sylvia W.A. Kamerling,Tineke Kraaij,Jaap Bakker,Hans Ulrich Scherer,Ton J. Rabelink,Reinhard Voll,Tobias Alexander,David Isenberg,Cees van Kooten,Y K Onno Teng	19
11	A High-throughput Assay to Assess and Quantify Neutrophil Extracellular Trap Formation 2019 ·Journal of Visualized Experiments ·(unknown),Laura S. van Dam,Tineke Kraaij,Sylvia W.A. Kamerling,Ton J. Rabelink,Cees van Kooten,Y K Onno Teng	7
12	A High-throughput Assay to Assess and Quantify Neutrophil Extracellular Trap Formation 2019 ·Journal of Visualized Experiments ·(unknown),Laura S. van Dam,Tineke Kraaij,Sylvia W.A. Kamerling,Ton J. Rabelink,Cees van Kooten,(unknown)	2
13	Excessive neutrophil extracellular trap formation in ANCA-associated vasculitis is independent of ANCA 2018 ·Kidney International ·Tineke Kraaij,Sylvia W.A. Kamerling,Laura S. van Dam,Jaap Bakker,Ingeborg M. Bajema,Theresa H. Page,Francesca Brunini,Charles D. Pusey,René E. M. Toes,Hans Ulrich Scherer,Ton J. Rabelink,Cees van Kooten,Y K Onno Teng	74
14	Clinical Implications of Excessive Neutrophil Extracellular Trap Formation in Renal Autoimmune Diseases 2018 ·Kidney International Reports ·Laura S. van Dam,Ton J. Rabelink,Cees van Kooten,Y K Onno Teng	32
15	Ex Vivo Induced Neutrophil Extracellular Traps Are Intrinsically Different in Anca-Associated Vasculitis and Systemic Lupus Erythematosus 2017 ·Arthritis & Rheumatism ·Laura S. van Dam,Tineke Kraaij,Sylvia W.A. Kamerling,Hans Ulrich Scherer,C D Pusey,Ton J. Rabelink,Cees van Kooten,(unknown)	1
16	Expression and clinical association of programmed cell death-1, programmed death-ligand-1 and CD8+ lymphocytes in primary sarcomas is subtype dependent 2017 ·Oncotarget ·(unknown),Yvonne M.H. Versleijen‐Jonkers,Melissa H.S. Hillebrandt-Roeffen,(unknown),Mark A.J. Gorris,Laura S. van Dam,Thomas Mentzel,Marije E. Weidema,C. Dilara Savci‐Heijink,Ingrid M.E. Desar,Johannes H. M. Merks,Max M. van Noesel,Janet Shipley,Winette T.A. van der Graaf,Uta Flucke,Friederike Meyer‐Wentrup	73
17	Deficiency of Nuclear Receptor Nur77 Aggravates Mouse Experimental Colitis by Increased NFκB Activity in Macrophages 2015 ·PLoS ONE ·Anouk A.J. Hamers,Laura S. van Dam,José Duarte,Mariska Vos,Goran Marinković,Claudia M. van Tiel,Sybren L. Meijer,(unknown),Stephan Huveneers,Anje A. te Velde,Wouter J. de Jonge,Carlie J.M. de Vries	53
18	The role of programmed cell death‐1 (PD‐1) and its ligands in pediatric cancer 2014 ·Pediatric Blood & Cancer ·Laura S. van Dam,(unknown),Friederike Meyer‐Wentrup	30

About Laura S. van Dam

Laura S. van Dam is a scholar working on Immunology and Allergy, Immunology and Rheumatology, having authored 18 papers that have together received 558 indexed citations. Recurring topics across this work include Vasculitis and related conditions (10 papers), Neutrophil, Myeloperoxidase and Oxidative Mechanisms (6 papers) and Cell Adhesion Molecules Research (5 papers). The work is most often cited by research in Immunology (302 citations), Rheumatology (138 citations) and Genetics (85 citations). Laura S. van Dam has collaborated with scholars based in Netherlands, United Kingdom and United States. Frequent co-authors include Ton J. Rabelink, Y K Onno Teng, Cees van Kooten, Jaap Bakker, Sylvia W.A. Kamerling, Tineke Kraaij, Hans Ulrich Scherer, Obbo W Bredewold, Friederike Meyer‐Wentrup and Charles D. Pusey. Their work appears in journals such as PLoS ONE, Kidney International and Frontiers in Immunology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact